IL31RA
Protein-coding gene in the species Homo sapiens
| IL31RA | |||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Identifiers | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Aliases | IL31RA, CRL, CRL3, GLM-R, GLMR, GPL, IL-31RA, PLCA2, PRO21384, hGLM-R, interleukin 31 receptor A, zcytoR17 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| External IDs | OMIM: 609510; MGI: 2180511; HomoloGene: 51395; GeneCards: IL31RA; OMA:IL31RA - orthologs | ||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| Wikidata | |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Interleukin-31 receptor A is a protein that in humans is encoded by the IL31RA gene.[5][6][7]
IL31RA is related to gp130 (IL6ST; MIM 600694), the common receptor subunit for IL6 (MIM 147620)-type cytokines. Oncostatin M receptor (OSMR; MIM 601743) and IL31RA form the heterodimeric receptor through which IL31 (MIM 609509) signals. Expression of IL31RA and OSMR mRNA is induced in activated monocytes, and both mRNAs are constitutively expressed in epithelial cells (Dillon et al., 2004).[supplied by OMIM][7]
References
- ^ a b c GRCh38: Ensembl release 89: ENSG00000164509 – Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000050377 – Ensembl, May 2017
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell SR, Haugen HS, Maurer M, Harder B, Johnston J, Bort S, Mudri S, Kuijper JL, Bukowski T, Shea P, Dong DL, Dasovich M, Grant FJ, Lockwood L, Levin SD, LeCiel C, Waggie K, Day H, Topouzis S, Kramer J, Kuestner R, Chen Z, Foster D, Parrish-Novak J, Gross JA (Jun 2004). "Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice". Nat Immunol. 5 (7): 752–60. doi:10.1038/ni1084. PMID 15184896. S2CID 12442845.
- ^ Ghilardi N, Li J, Hongo JA, Yi S, Gurney A, de Sauvage FJ (May 2002). "A novel type I cytokine receptor is expressed on monocytes, signals proliferation, and activates STAT-3 and STAT-5". J Biol Chem. 277 (19): 16831–6. doi:10.1074/jbc.M201140200. PMID 11877449.
- ^ a b "Entrez Gene: IL31RA interleukin 31 receptor A".
Further reading
- Strausberg RL, Feingold EA, Grouse LH, et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. Bibcode:2002PNAS...9916899M. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932.
- Clark HF, Gurney AL, Abaya E, et al. (2003). "The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment". Genome Res. 13 (10): 2265–70. doi:10.1101/gr.1293003. PMC 403697. PMID 12975309.
- Diveu C, Lelièvre E, Perret D, et al. (2004). "GPL, a novel cytokine receptor related to GP130 and leukemia inhibitory factor receptor". J. Biol. Chem. 278 (50): 49850–9. doi:10.1074/jbc.M307286200. PMID 14504285.
- Dreuw A, Radtke S, Pflanz S, et al. (2005). "Characterization of the signaling capacities of the novel gp130-like cytokine receptor". J. Biol. Chem. 279 (34): 36112–20. doi:10.1074/jbc.M401122200. PMID 15194700.
- Zhang Z, Henzel WJ (2005). "Signal peptide prediction based on analysis of experimentally verified cleavage sites". Protein Sci. 13 (10): 2819–24. doi:10.1110/ps.04682504. PMC 2286551. PMID 15340161.
- Gerhard DS, Wagner L, Feingold EA, et al. (2004). "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)". Genome Res. 14 (10B): 2121–7. doi:10.1101/gr.2596504. PMC 528928. PMID 15489334.
- Diveu C, Lak-Hal AH, Froger J, et al. (2005). "Predominant expression of the long isoform of GP130-like (GPL) receptor is required for interleukin-31 signaling". Eur. Cytokine Netw. 15 (4): 291–302. PMID 15627637.
- Bilsborough J, Leung DY, Maurer M, et al. (2006). "IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis". J. Allergy Clin. Immunol. 117 (2): 418–25. doi:10.1016/j.jaci.2005.10.046. PMID 16461143.
- v
- t
- e
- Agonists: Interleukin 1 (α, β)
- Mobenakin
- Pifonakin
- Antibodies: Canakinumab
- Gevokizumab
- Lutikizumab
- Decoy receptors: Rilonacept (IL-1 Trap)
- Agonists: Adargileukin alfa
- Aldesleukin
- Celmoleukin
- Denileukin diftitox
- Interleukin 2
- Pegaldesleukin
- Teceleukin
- Tucotuzumab celmoleukin
- Antibodies: Basiliximab
- Daclizumab (dacliximab)
- Inolimomab
- Agonists: Daniplestim
- Interleukin 3
- Leridistim
- Milodistim
- Muplestim
- Promegapoietin
- Agonists: Binetrakin
- Interleukin 4
- Interleukin 13
- Antagonists: Pitrakinra
- Antibodies: Dupilumab
- Pascolizumab
- Agonists: Interleukin 5
- Antagonists: YM-90709
- Antibodies: Benralizumab
- Mepolizumab
- Reslizumab
- Antisense oligonucleotides: TPI ASM8
- Agonists: Atexakin alfa
- Interleukin 6
- Antibodies: ARGX-109
- Clazakizumab
- Elsilimomab
- mAb 1339
- Olokizumab
- Sarilumab
- Siltuximab
- Sirukumab
- Tocilizumab
- Levilimab
- Agonists: Interleukin 7
- See CXCR1 (IL-8Rα) and CXCR2 (IL-8Rβ) here instead.
- Agonists: Interleukin 9
- Antibodies: Enokizumab
- Agonists: Ilodecakin
- Interleukin 10 (CSIF)
- Agonists: Interleukin 11 (AGIF)
- Oprelvekin
- Agonists: Edodekin alfa
- Interleukin 12
- Antibodies: Briakinumab
- Ustekinumab
- Agonists: Binetrakin
- Cintredekin besudotox
- Interleukin 4
- Interleukin 13
- Antibodies: Anrukinzumab
- Lebrikizumab
- Tralokinumab
- Agonists: ALT-803
- Interleukin 15
- Agonists: Interleukin 17 (A, B, C, D, E (interleukin 25), F)
- Antibodies: Brodalumab
- Ixekizumab
- Perakizumab
- Remtolumab
- Secukinumab
- Vunakizumab
- Agonists: Iboctadekin
- Interleukin 18
- Interleukin 37
- Tadekinig
- Binding proteins: IL18BP
- Agonists: Interleukin 19
- Interleukin 20
- Interleukin 24
- Antibodies: Fletikumab (against IL-20)
- Agonists: Denenicokin
- Interleukin 21
- Antibodies: NNC0114-0005
- NNC0114-0006
- Agonists: Interleukin 22
- Antibodies: Fezakinumab (against IL-22)
- Agonists: Interleukin 23 (SGRF)
- Antibodies: Brazikumab
- Briakinumab
- Guselkumab
- Risankizumab
- Tildrakizumab
- Ustekinumab
- Agonists: Interleukin 27 (interleukin 30)
- Agonists: Interferon λ4 (IFN-λ4)
- Interleukin 28 (A (IFN-λ2), B (IFN-λ3))
- Interleukin-29 (IFN-λ1)
- Agonists: Interleukin 31
- Agonists: Interleukin 33
- Agonists: Interleukin 36 (α, β, γ)
- Interleukin 38
- Antagonists: IL-36RA
| JAK |
|
|---|---|
| Others |
|
 | This article on a gene on human chromosome 5 is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
